Tsai H, Tsai K, Wu D, Huang Y, Lin M
Stem Cell Res Ther. 2025; 16(1):87.
PMID: 39988680
PMC: 11849191.
DOI: 10.1186/s13287-025-04223-7.
Liu W, Luo G
Neoplasia. 2024; 57:101059.
PMID: 39326322
PMC: 11470473.
DOI: 10.1016/j.neo.2024.101059.
Vasileiou M, Diamantoudis S, Tsianava C, Nguyen N
Curr Oncol. 2024; 31(6):3040-3063.
PMID: 38920716
PMC: 11203270.
DOI: 10.3390/curroncol31060232.
Dos Santos M, Godoi B, Da Silva N, Oliveira L, Ramos L, Cintra R
Lasers Med Sci. 2024; 39(1):135.
PMID: 38787412
DOI: 10.1007/s10103-024-04092-1.
Dai Y, Ji Z, Liang H, Jiang M, Wang L, Bao X
Cancer Sci. 2024; 115(7):2235-2253.
PMID: 38700108
PMC: 11247601.
DOI: 10.1111/cas.16200.
Long Non-Coding RNAs as Regulators for Targeting Breast Cancer Stem Cells and Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential.
Yang F, Yang Y, Qiu Y, Tang L, Xie L, Guan X
Cancers (Basel). 2024; 16(2).
PMID: 38254782
PMC: 10814583.
DOI: 10.3390/cancers16020290.
The BET degrader ZBC260 suppresses stemness and tumorigenesis and promotes differentiation in triple-negative breast cancer by disrupting inflammatory signaling.
Sharma D, Hager C, Shang L, Tran L, Zhu Y, Ma A
Breast Cancer Res. 2023; 25(1):144.
PMID: 37968653
PMC: 10648675.
DOI: 10.1186/s13058-023-01715-3.
Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin.
Bun A, Nagahashi M, Kuroiwa M, Komatsu M, Miyoshi Y
Breast Cancer Res Treat. 2023; 202(3):575-583.
PMID: 37733188
PMC: 10564839.
DOI: 10.1007/s10549-023-07086-9.
CAA-derived IL-6 induced M2 macrophage polarization by activating STAT3.
Zhao C, Zeng N, Zhou X, Tan Y, Wang Y, Zhang J
BMC Cancer. 2023; 23(1):392.
PMID: 37127625
PMC: 10152707.
DOI: 10.1186/s12885-023-10826-1.
Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment.
Habanjar O, Bingula R, Decombat C, Diab-Assaf M, Caldefie-Chezet F, Delort L
Int J Mol Sci. 2023; 24(4).
PMID: 36835413
PMC: 9964711.
DOI: 10.3390/ijms24044002.
Single-Cell Transcriptome Analysis Reveals Changes of Tumor Immune Microenvironment in Oral Squamous Cell Carcinoma After Chemotherapy.
Song H, Lou C, Ma J, Gong Q, Tian Z, You Y
Front Cell Dev Biol. 2022; 10:914120.
PMID: 35784460
PMC: 9247458.
DOI: 10.3389/fcell.2022.914120.
Macrophages Are a Double-Edged Sword: Molecular Crosstalk between Tumor-Associated Macrophages and Cancer Stem Cells.
Luo S, Yang G, Ye P, Cao N, Chi X, Yang W
Biomolecules. 2022; 12(6).
PMID: 35740975
PMC: 9221070.
DOI: 10.3390/biom12060850.
Chemotherapy-induced cytokines and prognostic gene signatures vary across breast and colorectal cancer.
Groysman L, Carlsen L, Huntington K, Shen W, Zhou L, El-Deiry W
Am J Cancer Res. 2022; 11(12):6086-6106.
PMID: 35018244
PMC: 8727797.
Inhibition of CXCR2 plays a pivotal role in re-sensitizing ovarian cancer to cisplatin treatment.
Henriques T, Dos Santos D, Santos Guimaraes I, Tessarollo N, Lyra-Junior P, Mesquita P
Aging (Albany NY). 2021; 13(10):13405-13420.
PMID: 34038868
PMC: 8202899.
DOI: 10.18632/aging.203074.
Cancer Stem Cells in the Immune Microenvironment.
Lee D, Oh K
Adv Exp Med Biol. 2021; 1187:245-266.
PMID: 33983582
DOI: 10.1007/978-981-32-9620-6_12.
Mechanistic Targets and Nutritionally Relevant Intervention Strategies to Break Obesity-Breast Cancer Links.
Bustamante-Marin X, Merlino J, Devericks E, Carson M, Hursting S, Stewart D
Front Endocrinol (Lausanne). 2021; 12:632284.
PMID: 33815289
PMC: 8011316.
DOI: 10.3389/fendo.2021.632284.
Bone Marrow Adipocytes, Adipocytokines, and Breast Cancer Cells: Novel Implications in Bone Metastasis of Breast Cancer.
Liu C, Zhao Q, Yu X
Front Oncol. 2020; 10:561595.
PMID: 33123472
PMC: 7566900.
DOI: 10.3389/fonc.2020.561595.
NAC1 attenuates BCL6 negative autoregulation and functions as a BCL6 coactivator of FOXQ1 transcription in cancer cells.
Gao M, Herlinger A, Wu R, Wang T, Shih I, Kong B
Aging (Albany NY). 2020; 12(10):9275-9291.
PMID: 32412910
PMC: 7288929.
DOI: 10.18632/aging.103203.
HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.
Kale S, Korcum A, Dundar E, Erin N
Naunyn Schmiedebergs Arch Pharmacol. 2019; 393(2):253-262.
PMID: 31522240
DOI: 10.1007/s00210-019-01725-z.
MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
Weng Y, Tseng H, Chen Y, Shen P, Haq A, Chen L
Mol Cancer. 2019; 18(1):42.
PMID: 30885232
PMC: 6421700.
DOI: 10.1186/s12943-019-0988-0.